Fibrotic process and drug metabolism in alcoholic liver disease
- PMID: 3720178
- DOI: 10.1038/clpt.1986.138
Fibrotic process and drug metabolism in alcoholic liver disease
Abstract
The effect of fibrosis on drug metabolism in alcoholic liver disease was evaluated in a comparison of the concentrations of serum aminoterminal propeptide of type III procollagen and basement membrane (BM; 7S domain of type IV collagen and laminin) antigens with in vitro (cytochrome P-450) and in vivo (antipyrine) drug metabolism in 67 alcoholics classified by liver histology. Alcoholics with intact or fatty liver had rapid or normal drug metabolism and normal collagen metabolism. Alcoholics with a fatty liver plus fibrosis or active cirrhosis had reduced drug metabolism and elevated levels of serum markers for collagen and BM metabolism. Alcoholics with inactive cirrhosis who had received therapy with enzyme inducers had a tendency toward normal drug and collagen metabolism parameters. Antipyrine metabolism, but not P-450 content, was related to the levels of serum type III collagen and BM markers. The fibrotic process, especially BM formation, creates a mechanical barrier that may prevent contact between blood and hepatocytes, thus delaying substrate availability.
Similar articles
-
Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease.Eur J Clin Invest. 1985 Jun;15(3):132-7. doi: 10.1111/j.1365-2362.1985.tb00156.x. Eur J Clin Invest. 1985. PMID: 3926506
-
Serum zinc and serum copper and indices of drug metabolism in alcoholics.Eur J Clin Pharmacol. 1977 Oct 14;12(2):147-51. doi: 10.1007/BF00645136. Eur J Clin Pharmacol. 1977. PMID: 923628
-
Liver size and indices of drug metabolism in alcoholics.Eur J Clin Pharmacol. 1978 Mar 17;13(1):61-7. doi: 10.1007/BF00606684. Eur J Clin Pharmacol. 1978. PMID: 639835
-
Drug metabolism in alcoholics.Pharmacol Ther. 1982;16(2):261-8. doi: 10.1016/0163-7258(82)90057-2. Pharmacol Ther. 1982. PMID: 6752978 Review.
-
Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease.Anat Rec (Hoboken). 2017 Aug;300(8):1371-1390. doi: 10.1002/ar.23567. Epub 2017 Feb 28. Anat Rec (Hoboken). 2017. PMID: 28187500 Review.
Cited by
-
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004. Clin Pharmacokinet. 1991. PMID: 2029802 Review.
-
Antipyrine clearance and metabolite formation in primary biliary cirrhosis.Dig Dis Sci. 2001 Feb;46(2):352-9. doi: 10.1023/a:1005661117739. Dig Dis Sci. 2001. PMID: 11281185
-
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.Br J Clin Pharmacol. 1990 Mar;29(3):289-97. doi: 10.1111/j.1365-2125.1990.tb03638.x. Br J Clin Pharmacol. 1990. PMID: 2310653 Free PMC article.
-
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.Br J Clin Pharmacol. 1995 Jan;39(1):71-6. doi: 10.1111/j.1365-2125.1995.tb04412.x. Br J Clin Pharmacol. 1995. PMID: 7756103 Free PMC article.
-
Clinical pharmacokinetics in patients with liver disease.Clin Pharmacokinet. 1991 Jul;21(1):42-69. doi: 10.2165/00003088-199121010-00004. Clin Pharmacokinet. 1991. PMID: 1914341 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical